ABRF Annual Meeting 2019

Event

Sat, Mar 23 2019 to Tue, Mar 26 2019
The Alamo

The ABRF (Association of Biomolecular Resource Facilities) 2019 Annual Meeting will take place in Henry B. Gonzalez Convention Center in San Antonio from March 23-26, 2019. The Henry B. Gonzalez Convention Center is located near the banks of the River Walk in downtown.

The ABRF meeting is not just for OMICS-centric researchers! ABRF is expanding in new directions making it the must-attend meeting for core facility professionals of all disciplines. Highlights of the ABRF annual meeting include scientific sessions and workshops that allow presenters and attendees to ... Read more

Presentation

Presenter Dr. Todd M. Smith, Digital World Biology, provided and overview of the session. Read more

Presentation

Dr. Linnea Fletcher shared information about biotechnology education in community colleges and Austin's biotech incubator. Read more

Presentation

Presenter: Ms. Abbe Kesterson explained Contract Service Organizations, work on building a CSO community and projects at Blue Grass Community and Technical College. Read more

Presentation

Presenter: Dr. Tyler Drake discussed progress made by the colleges biotech incubator. Read more

Presentation

Presenter Dr. Thomas Tubon, shared information about the consortium for advanced manufacturing of cell and tissue based products. Read more

Presentation

Immuno-biotechnology is one of the fastest growing areas in the field of biotechnology. Digital World Biology’s Biotech-Careers.org database of nearly 7000 biotechnology employers has nearly 700 organizations that are involved with immunology in some way. With the advent of advanced DNA sequencing, and other technologies, immuno-biotechnology has significantly increased the use of computing technologies to decipher the meaning of large datasets and predict interacBons between immune receptors (anBbodies / T-Cell receptors / MHC) and their targets. The use of new technologies like immune-profiling - where large numbers of immune receptors are sequenced en masse - and targeted cancer therapies - ... Read more